Alvogen Claims Lead On Lenalidomide In Europe
Alvogen is claiming the first European launch of a generic rival to Revlimid, rolling out the oncology drug in several central and eastern European markets. Meanwhile, IPR challenges to three Revlimid patents in the US have been denied.
You may also be interested in...
Firms that achieved recognition at last year’s Global Generics & Biosimilars Awards have continued to build on that success in the months since.
Alvogen can sell in the US generic lenalidomide on a volume-limited basis after March 2022, and without volume limitations in early 2026, after settling patent litigation with Celgene relating to the originator’s Revlimid. Dr Reddy's has also settled in Canada.
Alvogen’s Lotus subsidiary and Cambrex are expanding their manufacturing capabilities in Taiwan and Canada respectively. As several firms reveal the results of FDA inspections, the agency slaps United Exchange Corporation with a warning letter.